TY - JOUR
T1 - Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia
T2 - A prospective, randomized trial of safety and immunogenicity
AU - Safdar, Amar
AU - Rodriguez, Gilhen H.
AU - Rueda, Adriana M.
AU - Wierda, William G.
AU - Ferrajoli, Alessandra
AU - Musher, Daniel M.
AU - O'Brien, Susan
AU - Koller, Charles A.
AU - Bodey, Gerald P.
AU - Keating, Michael J.
PY - 2008/7/15
Y1 - 2008/7/15
N2 - BACKGROUND. For the current study, the authors sought to determine whether administration of multiple-dose granulocyte-macrophage-colony-stimulating factor (GM-CSF) could improve response to standard 23-valent polysaccharide pneumococcal vaccine (PPV) in patients with chronic lymphocytic leukemia (CLL). METHODS. Patients were allocated randomly to receive PPV either alone or with 3 doses of GM-CSF (250 μg) given before or after vaccination. Serum was obtained before, 4 weeks after, and 12 weeks after vaccination for antibody determination. Thirty-two patients with CLL were given PPV. They were randomized to receive 3 doses of GM-CSF either before or after vaccination or to receive no GM-CSF. RESULTS. A 4-fold rise in immunoglobulin G (IgG) to capsular polysaccharides from Streptococcus pneumoniae types 4, 6B, 9V, 14, 19F, and 23F occurred in <10% of patients in each of the 3 groups. There were no differences in geometric mean IgG levels in any of the 3 groups 4 weeks or 12 weeks after vaccination. CONCLUSIONS. In patients with CLL, the response to pure polysaccharide pneumococcal vaccine was low despite immune enhancement with multiple doses of GM-CSF. In all patients, reactogenicity was minor.
AB - BACKGROUND. For the current study, the authors sought to determine whether administration of multiple-dose granulocyte-macrophage-colony-stimulating factor (GM-CSF) could improve response to standard 23-valent polysaccharide pneumococcal vaccine (PPV) in patients with chronic lymphocytic leukemia (CLL). METHODS. Patients were allocated randomly to receive PPV either alone or with 3 doses of GM-CSF (250 μg) given before or after vaccination. Serum was obtained before, 4 weeks after, and 12 weeks after vaccination for antibody determination. Thirty-two patients with CLL were given PPV. They were randomized to receive 3 doses of GM-CSF either before or after vaccination or to receive no GM-CSF. RESULTS. A 4-fold rise in immunoglobulin G (IgG) to capsular polysaccharides from Streptococcus pneumoniae types 4, 6B, 9V, 14, 19F, and 23F occurred in <10% of patients in each of the 3 groups. There were no differences in geometric mean IgG levels in any of the 3 groups 4 weeks or 12 weeks after vaccination. CONCLUSIONS. In patients with CLL, the response to pure polysaccharide pneumococcal vaccine was low despite immune enhancement with multiple doses of GM-CSF. In all patients, reactogenicity was minor.
KW - Chronic lymphocytic leukemia
KW - Granulocyte-macrophage-colony-stimulating factor
KW - Immunogenicity
KW - Pneumococcal vaccine
KW - Reactogenicity
KW - Streptococcus pneumonia
UR - http://www.scopus.com/inward/record.url?scp=48249092979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48249092979&partnerID=8YFLogxK
U2 - 10.1002/cncr.23561
DO - 10.1002/cncr.23561
M3 - Article
C2 - 18470901
AN - SCOPUS:48249092979
SN - 0008-543X
VL - 113
SP - 383
EP - 387
JO - Cancer
JF - Cancer
IS - 2
ER -